市场调查报告书
商品编码
1237809
全球宫内节育器市场——规模、按产品、按年龄组、行业分析报告、区域展望、增长潜力、适用性、竞争对手份额和预测,2023-2032 年Intrauterine Devices Market Size, By Product, By Age Group, Industry Analysis Report, Regional Outlook, Growth Potential, Application Potential, Competitive Market Share & Forecast, 2023-2032 |
由于人们越来越倾向于计划晚孕,预计到 2032 年,全球宫内避孕药市场将显着增长。
但是,与其他具有成本效益的替代品相比,宫内节育器价格昂贵,因此影响了整个市场的增长。 鑑于意外出生人数的增加、堕胎率的上升和健康状况的下降,各国政府正在努力通过提供宫内节育器作为一种避孕选择来提高认识并扩大妇女的能力。 它们的低渗透率,尤其是在发展中地区,受到高购置成本的阻碍。
另一方面,宫内避孕药的使用增加是由于意外怀孕的发生率上升以及与口服药等替代避孕方法相关的副作用,这对市场增长产生了积极影响。人们认为之前
领先的公司正在开发新的和先进的避孕方案,以提高市场竞争力。 例如,2021 年 8 月,拜耳公司获得 FDA 批准,其宫内节育器 (IUD) Mirena 52mg 升级版可用于长达 7 年的预防妊娠。 该批准使该公司能够加强其宫内节育器产品线,从而增加收入。
宫内节育器市场在产品、年龄组和地区方面存在分歧。
从 2023 年到 2032 年,20-24 岁年龄段的复合年增长率预计将达到 6%。 由于宣传活动和这些装置提供的额外健康益处,年轻成年女性越来越多地使用宫内节育器。 使用长效避孕药,如激素宫内节育器 (IUD) 和铜,可以减少女性意外怀孕的频率,并可能增加年轻人对避孕药的采用。我有。
按地区划分,预计到 2032 年北美的宫内节育器市场将显着扩大。 北美的强大市场地位可归因于多种因素,包括对创新避孕方法(包括宫内节育器)的普遍了解增加,以及该地区意外怀孕率立即下降。 根据美国国家生物技术信息中心 (NCBI) 的一份报告,美国每年大约有 100 万例堕胎。 2017 年至 2019 年间,美国约有 70% 参加计划生育计划的女性使用了某种形式的避孕措施。
Global Intrauterine Devices Market is expected to grow considerably through 2032 owing to the increasing preference for planned delayed pregnancy.
However, the high cost of intrauterine devices as compared to the other cost-effective alternatives has put a strain on the overall market growth. In light of the increased prevalence of unwanted births, growing abortion rates, health degradation, and other factors, governments are working on expanding their capabilities by raising knowledge and offering IUDs as a contraceptive option to women. Its low adoption rate, particularly in developing areas, is hampered by its high acquisition costs.
On the other hand, the increasing usage of intrauterine devices can be credited to the rising incidence of unwanted pregnancies and the adverse effects associated with alternative contraceptive methods, such as oral pills, which has favorably impacted market growth.
Leading companies are creating new and advanced options for preventing pregnancies to score a competitive edge in the market. For instance, in August 2021, Bayer AG received FDA approval for an upgrade of the Intrauterine Device (IUD) Mirena 52 mg for a maximum of seven years of preventing pregnancy. The approval has enabled the company to enhance its intrauterine device product line, resulting in increased revenue creation.
The intrauterine devices market has been bifurcated in terms of product, age group, and region.
Based on the age group, the 20-24 age segment is slated to grow at 6% CAGR from 2023 to 2032. Young adult women are increasingly using IUDs due to awareness campaigns and additional health advantages provided by these devices. The prevalence of unwanted pregnancies among women may be reduced using long-acting contraception including hormonal intrauterine devices (IUDs) and coppers, fostering the production adoption amongst young population.
From the regional perspective, the North America intrauterine devices market is speculated to witness notable expansion by 2032. The high market position held by North America can be credited to a variety of factors, including growing public knowledge of innovative contraceptive methods including IUDs, which have resulted in an immediate drop in unplanned pregnancies in the region. According to a National Center of Biotechnology Information (NCBI) report, approximately 1 million abortions take place in the United States each year. Also, approximately 70% of female family planning recipients in the United States used some kind of contraception between 2017 and 2019.